Cosmo Pharmaceuticals Nv Stock Performance
| CMOPF Stock | USD 135.00 1.50 1.12% |
On a scale of 0 to 100, Cosmo Pharmaceuticals holds a performance score of 18. The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cosmo Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cosmo Pharmaceuticals is expected to be smaller as well. Please check Cosmo Pharmaceuticals' maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to make a quick decision on whether Cosmo Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cosmo Pharmaceuticals NV are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Cosmo Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 185.9 M | |
| Total Cashflows From Investing Activities | 24.9 M |
Cosmo |
Cosmo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 8,132 in Cosmo Pharmaceuticals NV on September 30, 2025 and sell it today you would earn a total of 5,368 from holding Cosmo Pharmaceuticals NV or generate 66.01% return on investment over 90 days. Cosmo Pharmaceuticals NV is currently producing 0.8559% returns and takes up 3.6778% volatility of returns over 90 trading days. Put another way, 33% of traded pink sheets are less volatile than Cosmo, and 83% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cosmo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cosmo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cosmo Pharmaceuticals NV, and traders can use it to determine the average amount a Cosmo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2327
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CMOPF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Cosmo Pharmaceuticals is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cosmo Pharmaceuticals by adding it to a well-diversified portfolio.
Cosmo Pharmaceuticals Fundamentals Growth
Cosmo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cosmo Pharmaceuticals, and Cosmo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cosmo Pink Sheet performance.
| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 | |||
| Profit Margin | 0.45 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.02 B | |||
| Shares Outstanding | 16.38 M | |||
| Price To Earning | 21.69 X | |||
| Price To Book | 2.12 X | |||
| Price To Sales | 15.66 X | |||
| Revenue | 65.07 M | |||
| EBITDA | 40.36 M | |||
| Cash And Equivalents | 218.96 M | |||
| Cash Per Share | 13.36 X | |||
| Total Debt | 167.15 M | |||
| Debt To Equity | 0.37 % | |||
| Book Value Per Share | 28.23 X | |||
| Cash Flow From Operations | 12.61 M | |||
| Earnings Per Share | 2.31 X | |||
| Total Asset | 805.56 M | |||
About Cosmo Pharmaceuticals Performance
By analyzing Cosmo Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Cosmo Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cosmo Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cosmo Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. Cosmo Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 292 people.Things to note about Cosmo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cosmo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cosmo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cosmo Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| About 47.0% of the company shares are held by company insiders |
- Analyzing Cosmo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cosmo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cosmo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cosmo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cosmo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cosmo Pharmaceuticals' pink sheet. These opinions can provide insight into Cosmo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cosmo Pink Sheet analysis
When running Cosmo Pharmaceuticals' price analysis, check to measure Cosmo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cosmo Pharmaceuticals is operating at the current time. Most of Cosmo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cosmo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cosmo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cosmo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |